Source-grounded facts extracted from DNA X, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
DNA X, Inc. reported the second quarter ended June 30, 2023 results: revenue $26.8 million, net income $509 thousand.
“● Net revenues increased 125% year-over-year to $26.8 million, from $12.0 million in the second quarter 2022, and increased sequentially from $25.8 million in the first quarter 2023 ● Achieved positive GAAP net income of $509 thousand, compared to a net loss of $4.2 million in the second quarter of 2022, and a net profit of $227 thousand in the first quarter 2023”
Jose C. Principe retired as Director at DNA X, Inc..
“On August 3, 2023, Jose C. Principe informed the Board of his decision to retire from, and not stand for re-election to the Board, effective as of the end of his term, the date of the conclusion of the Company’s 2023 annual meeting of stockholders.”
Alan Howe retired as Director at DNA X, Inc..
“On August 3, 2023, Alan Howe informed the board of directors (the “Board”) of Sonim Technologies, Inc. (the “Company”) of his decision to retire from, and not stand for re-election to the Board, effective as of the end of his term, the date of the conclusion of the Company’s 2023 annual meeting of stockholders.”
DNA X, Inc. reported first quarter ended March 31, 2023 results: revenue $25.8 million, net income positive GAAP net income of $227 thousand.
“reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 and Recent Highlights ● Net revenues increased 95% year-over-year to $25.8 million, from $13.3 million in the first quarter 2022, and 7% sequentially from $24.1 million in the fourth quarter 2022 ● Achieved positive GAAP net income of $227 thousand, compared to a net loss of $7.2 million in the first quarter of 2022, and a net loss of $1.0 million in the fourth quarter 2022”
DNA X, Inc. reported the first quarter of 2023 results: revenue approximately $25.8 million.
“Sonim Technologies (Nasdaq: SONM) today announced that it expects to report continued sequential and year-over-year sales growth in the first quarter of 2023, ended March 31. First quarter 2023 revenue is anticipated to be approximately $25.8 million.”
DNA X, Inc. reported the third quarter ended September 30, 2022 results: revenue $20.5 million, net income $1.6 million.
“● Net revenues increased 42% year-over-year to $20.5 million, from $14.4 million in the third quarter 2021, and 72% sequentially from $12.0 million in the second quarter 2022 ● Net loss declined to $1.6 million, from a net loss of $10.9 million in the third quarter of 2021 and from a net loss of $4.2 million in the second quarter 2022”
DNA X, Inc. shareholders approved Ratification of Moss Adams as independent registered public accounting firm at the 2022-10-26 meeting.
“Proposal 4 : The stockholders, on an advisory basis, ratified the appointment of Moss Adams as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 26,955,843 613,682 96,146 N/A”
DNA X, Inc. shareholders approved Amendment to Certificate of Incorporation to effect reverse stock split at the 2022-10-26 meeting.
“Proposal 3 : A proposal to amend the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s common stock, pursuant to which any whole number of outstanding shares between and including two (2) and fifteen (15) shares would be combined, converted and changed into one (1) share of common stock, with the final exchange ratio to be determined by the Company’s board of directors in its discretion, was approved as set forth below: Votes For Votes Against Votes Abstained Broker Non-Votes 26,257,914 1,368,772 38,985 N/A”
DNA X, Inc. shareholders approved Amendment to Plan to increase authorized shares by 5,000,000 at the 2022-10-26 meeting.
“Proposal 2 : The stockholders approved an amendment to the Plan to increase the aggregate number of shares of common stock authorized for issuance by 5,000,000 shares, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 21,578,652 1,104,564 20,891 4,961,564”
DNA X, Inc. shareholders approved Election of seven director nominees at the 2022-10-26 meeting.
“Proposal 1 : The stockholders elected each of the seven director nominees to the Board of Directors of the Company to serve until the next annual meeting and until his or her successor has been duly elected and qualified, as follows: Name Votes For Votes Withheld Broker Non-Votes Mike Mulica 21,968,984 735,123 4,961,564 Alan Howe 22,119,741 584,366 4,961,564 Jeffrey Wang 22,150,044 554,063 4,961,564 Jack Steenstra 22,137,165 566,942 4,961,564 James Cassano 22,137,566 566,541 4,961,564 Peter Liu 22,147,770 556,337 4,961,564 Jose C. Principe 22,137,147 566,960 4,961,564”
Peter Hao Liu was appointed as Chief Executive Officer at DNA X, Inc..
“On August 20, 2022, Sonim Technologies, Inc., a Delaware corporation (the “ Company ”), entered into an employment agreement (the “ Employment Agreement ”) with Peter Hao Liu in connection with his role as Chief Executive Officer (“ CEO ”) of the Company.”
Jose Carlos Principe was elected as Director at DNA X, Inc..
“On July 14, 2022, the board of directors (the “Board”) of Sonim Technologies, Inc., a Delaware corporation (the “Company”) elected Messrs. Peter Hao Liu and Jose Carlos Principe, Ph.D., to serve as members of the Board, effective July 14, 2022.”
Peter Hao Liu was elected as Director at DNA X, Inc..
“On July 14, 2022, the board of directors (the “Board”) of Sonim Technologies, Inc., a Delaware corporation (the “Company”) elected Messrs. Peter Hao Liu and Jose Carlos Principe, Ph.D., to serve as members of the Board, effective July 14, 2022.”
Jeffrey Wang was appointed as Director, Chairman of the Board at DNA X, Inc..
“Jeffrey Wang, Director, Chairman of the Board”
Clay Crolius was appointed as Chief Financial Officer at DNA X, Inc..
“the Board appointed Clay Crolius as Chief Financial Officer (principal financial and accounting officer) of the Company.”
Robert Tirva resigned as President, Chief Financial Officer and Chief Operating Officer at DNA X, Inc..
“On July 13, 2022, Robert Tirva, President, Chief Financial Officer and Chief Operating Officer (principal financial and accounting officer) of the Company resigned from his positions with the Company and its affiliates.”
Sue Swenson resigned as Director at DNA X, Inc..
“John Kneuer and Sue Swenson resigned from the Board and each respective committee of the Board to which they were appointed.”
John Kneuer resigned as Director at DNA X, Inc..
“John Kneuer and Sue Swenson resigned from the Board and each respective committee of the Board to which they were appointed.”
Robert Tirva was terminated as President, Chief Financial Officer and Chief Operating Officer at DNA X, Inc..
“On April 13, 2022, the Compensation Committee of the Board of Directors of the Company approved a letter agreement with Robert Tirva, the Company’s President, Chief Financial Officer and Chief Operating Officer. The agreement provides that Mr. Tirva’s employment with the Company will terminate on, and subject to, the First Closing and that upon such termination, Mr. Tirva would be entitled to receive”
Peter Liu was appointed as Chief Executive Officer at DNA X, Inc..
“on April 13, 2022, the board of directors of Sonim appointed Peter Liu as Chief Executive Officer of the Company”
Kenny Young resigned as member of the Board of Directors at DNA X, Inc..
“On February 3, 2022, Kenny Young resigned as a member of the Board of Directors of Sonim Technologies, Inc. (the “Company”), effective immediately.”
Ken Naumann resigned as Director at DNA X, Inc..
“On July 16, 2021, Ken Naumann resigned as a member of the Board of Directors of Sonim Technologies, Inc. (the “Company”), effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.